8-K: Aytu BioPharma Highlights EXXUA Launch & Growth Strategy

Aytu BioPharma recapped its Investor Day, focusing on the commercial launch and market opportunity for EXXUA, its novel antidepressant for Major Depressive Disorder.

Summary

• Aytu BioPharma held an Investor Day on January 20, 2026, primarily focusing on EXXUA (gepirone) extended-release tablets, the first and only 5HT1a agonist approved by the FDA for Major Depressive Disorder (MDD).
• EXXUA was initially launched in December 2025, with the full commercial launch now underway following the completion of sales force training on January 16, 2026.
• Key opinion leaders highlighted EXXUA's mechanism of action, which specifically activates the 5HT1a receptor, promoting antidepressant effects without the sexual dysfunction, insomnia, anxiety, or weight gain associated with SSRIs and SNRIs.
• Clinical studies demonstrated EXXUA's statistically significant improvement in HAM-D17 total scores at Week 8 compared to placebo (P=0.018 and P=0.032) and statistically significant remission as early as Week 3.
• The most common adverse reactions were dizziness, nausea, insomnia, abdominal pain, and dyspepsia (incidence of 5% and twice the incidence of placebo), with a discontinuation rate due to adverse events of 7% for EXXUA versus 3% for placebo.
• The U.S. MDD market is valued at over $22 billion, with more than 345 million antidepressant prescriptions written annually.
• Aytu's financial highlights as of September 30, 2025, include $32.6 million in cash, a trailing twelve months (TTM) adjusted EBITDA of $6.7 million, and TTM operating cash burn of $1.4 million.
• The EXXUA launch investment budget was reduced from $10 million to $6-8 million due to efficiencies, and EXXUA is expected to have a gross margin of 66-68%.
• The company has a term loan outstanding of $12.5 million and reduced high-interest liabilities by $7.4 million in the TTM.
• The commercial strategy includes a 40+ person sales force, a virtual sales team, a rolling Contract Sales Organization model, targeted consumer promotion, and the Aytu RxConnect patient access program, which guarantees 100% coverage for commercially insured patients with a maximum $50 copay.
• Aytu is not initially pursuing first-line use for EXXUA and expects early favorable coverage for Medicaid and Medicare patients depending on geography.

Sentiment

Score: 7

Explanation: The filing presents a positive outlook on the commercial launch of EXXUA, highlighting its unique product profile addressing significant unmet needs in MDD, strong financial position with sufficient cash, and efficient launch strategy. While standard drug-related risks are present, the overall tone and reported early traction are favorable.

Positives

• EXXUA is the first and only 5HT1a agonist approved by the FDA for MDD, offering a novel mechanism of action compared to existing treatments.
• EXXUA demonstrates a neutral sexual profile and no clinically significant increase in body weight, addressing significant unmet needs and common side effects of other antidepressants.
• Statistically significant improvement in MDD symptoms and remission achieved as early as week 3 in pivotal studies.
• Early signs post-launch are described as very positive, with distributors fully stocked and initial prescriptions generated.
• The U.S. MDD market is substantial, valued at over $22 billion with 345 million annual prescriptions, indicating a large opportunity for EXXUA.
• Aytu BioPharma reported $32.6 million in cash as of September 30, 2025, with no additional cash requirement expected through profitability.
• The EXXUA launch investment budget was reduced from $10 million to $6-8 million due to efficiencies and cost management.
• EXXUA is expected to achieve a strong gross margin of 66-68%, comparable to the company's TTM companywide gross margin of 67.6%.
• The company reduced high-interest liabilities by $7.4 million in the trailing twelve months.
• The Aytu RxConnect program offers predictable coverage and affordable access for commercially insured patients, capping out-of-pocket costs at $50 for EXXUA prescriptions.

Negatives

• EXXUA carries a Boxed WARNING regarding increased risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies, though EXXUA is not approved for pediatric use.
• EXXUA prolongs the QTc interval, requiring ECG and electrolyte monitoring, and is contraindicated in patients with prolonged QTc interval > 450 msec at baseline or congenital long QT syndrome.
• The most common adverse reactions (dizziness, nausea, insomnia, abdominal pain, and dyspepsia) occurred at an incidence of 5% and at least twice the incidence of placebo.
• Discontinuation due to adverse events was 7% for EXXUA, compared to 3% for placebo, indicating a higher rate of treatment cessation due to side effects.
• Concomitant use with strong CYP3A4 inhibitors is contraindicated, and the dose must be reduced with moderate CYP3A4 inhibitors.
• EXXUA is contraindicated in patients with severe hepatic impairment and with MAOIs due to the risk of serious drug interactions, including serotonin syndrome.

Risks

• Suicidal thoughts and behaviors in adolescents and young adults, as antidepressants increase this risk in short-term studies (EXXUA is not approved for pediatric patients).
• QT prolongation, which can lead to serious cardiac arrhythmias; EXXUA is contraindicated in patients with prolonged QTc interval > 450 msec at baseline, congenital long QT syndrome, or severe hepatic impairment, and requires careful monitoring.
• Serotonin Syndrome, a potentially life-threatening condition, can occur with concomitant use of EXXUA with SSRIs, tricyclic antidepressants, or MAOIs (concomitant use with MAOIs is contraindicated).
• Activation of Mania or Hypomania, as antidepressant treatment can precipitate manic episodes, especially in patients with bipolar disorder or risk factors for it (EXXUA is not approved for bipolar depression).
• Drug interactions with CYP3A4 inhibitors, requiring dose reduction or contraindication depending on the inhibitor's strength.
• Contraindication in patients with severe hepatic impairment (Child-Pugh C).

Future Outlook

Aytu BioPharma expects to provide periodic updates on EXXUA's commercial launch performance during quarterly earnings calls and investor events, with the launch strategy designed for efficient, scalable expansion of promotional resources as cash flows allow. The company anticipates no additional cash requirements through profitability and aims to continue building out its KOL network and publication plan.

Management Comments

• Josh Disbrow, CEO, views EXXUA as a 'truly unique opportunity' representing a novel way of treating MDD, and commented on 'early positive signs' in the days following initial product availability and full commercial launch.
• Ryan Selhorn, CFO, stated that 'no additional cash requirement expected through profitability' and highlighted the reduction of the EXXUA launch investment budget due to efficiencies.

Industry Context

The launch of EXXUA introduces a novel 5HT1a agonist into the substantial U.S. Major Depressive Disorder market, which is currently dominated by SSRIs and SNRIs. EXXUA's differentiated mechanism of action, particularly its neutral sexual profile and lack of significant weight gain, addresses key unmet needs and common side effects associated with existing antidepressant classes, potentially positioning it as a valuable alternative for patients dissatisfied with current treatments. This strategic positioning aims to capture market share in a highly competitive but large therapeutic area.

Comparison to Industry Standards

• EXXUA's neutral sexual profile and lack of clinically significant weight gain differentiate it from many SSRIs and SNRIs, which are associated with sexual dysfunction (approximately 50% of patients) and weight gain (up to 65% with long-term use).
• The expected gross margin for EXXUA (66-68%) is comparable to the company's TTM companywide gross margin of 67.6%, indicating a healthy product margin within the pharmaceutical industry, aligning with typical margins for branded specialty pharmaceuticals.
• The MDD market size of over $22 billion and 345 million annual prescriptions highlights a significant opportunity, aligning with the large market potential seen by other successful antidepressant launches, such as those from major pharmaceutical companies like Eli Lilly (Prozac, Cymbalta) or Pfizer (Zoloft).
• The company's patient access program, Aytu RxConnect, with its guaranteed 100% coverage for commercially insured patients and capped $50 copay, aims to reduce patient out-of-pocket costs and improve access, a critical factor for new drug adoption in a market with diverse payer landscapes.

Stakeholder Impact

• Shareholders: Potential for increased revenue and profitability from EXXUA launch, supported by strong gross margins and efficient commercialization, which could positively impact share value.
• Patients with MDD: Access to a novel antidepressant (EXXUA) with a differentiated mechanism of action, potentially offering relief without common side effects like sexual dysfunction and weight gain, facilitated by the Aytu RxConnect program for affordable access.
• Healthcare Providers (Psychiatrists): A new treatment option for MDD patients, particularly those who fail to achieve remission or experience side effects with existing SSRIs/SNRIs, supported by targeted sales efforts and medical education.
• Employees: Continued employment and potential growth opportunities within the sales and commercial teams as EXXUA scales, especially with the planned expansion of promotional resources.

Next Steps

• Aytu will provide periodic updates to investors during quarterly earnings calls and investor events regarding EXXUA's performance.
• The company plans for continued expansion of promotional resources for EXXUA as cash flows allow.
• Ongoing efforts to build out a Key Opinion Leader (KOL) network and execute a strong publication and meeting plan are in place.
• Further contracting for EXXUA with payers, including Medicaid and Medicare, is expected.

Key Dates

Recommendation

While the commercial launch of EXXUA is underway with positive early signs and a differentiated product profile addressing unmet needs in MDD, it is still in its initial phase. The company's financial position appears stable with sufficient cash and reduced liabilities, and the expected gross margin for EXXUA is strong. However, the success of a new drug launch carries inherent risks related to market adoption, payer coverage, and competitive landscape. A 'hold' recommendation is prudent until more definitive sales data and market penetration figures for EXXUA become available to assess its long-term revenue generation potential and impact on overall profitability.

Keywords

Aytu BioPharma, AYTU, EXXUA, gepirone, Major Depressive Disorder, MDD, antidepressant, 5HT1a agonist, pharmaceuticals, drug launch, investor day, CNS diseases, psychiatry, FDA approval, patient access program